Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis. Issue 12 (23rd October 2020)

• Record Type: Journal Article
• Authors: Saad, Anasemon; Young, McKenzie R.; Studtmann, Anna E.; Autry, Elizabeth B.; Schadler, Aric; Beckman, Elizabeth J.; Gardner, Brian M.; Wurth, Mark A.; Kuhn, Robert J.
• Is Part Of: Pediatric pulmonology. Volume 55:Issue 12(2020)
• Page Start: 3384
• Page End: 3390
• Publication Date: 2020-10-23
• Subjects: aminoglycosides -- cumulative exposure -- cystic fibrosis -- renal dysfunction; Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.25066
• Languages: English
• ISSNs: 8755-6863

Abstract

Abstract: Cystic fibrosis (CF) patients, with Pseudomonas aeruginosa infection, often require repeated aminoglycoside courses for the management of acute pulmonary exacerbations (APEs). Acute kidney injury (AKI) due to aminoglycosides has been reported; little data exist regarding long‐term nephrotoxicity with repeated exposure. The objective of this study was to describe the incidence of acute and chronic nephrotoxicity due to cumulative intravenous (IV) aminoglycoside exposure. This is a retrospective, observational study of pediatric and adult CF patients admitted to an academic medical center between January 1, 2006 and October 1, 2018 for APE management. Patients were eligible for inclusion if they received at least five courses of an IV aminoglycoside for at least 7 days each. Cumulative weight‐based aminoglycoside dose was reported in milligrams per kilogram. For each admission, baseline and highest serum creatinine were collected to assess the incidence of AKI. The baseline and final estimated glomerular filtration rate (eGFR) were calculated to assess long‐term effects on renal function. Sixty‐six patients, representing greater than 700 courses, were included in the final analysis. The median cumulative weight‐based aminoglycoside dose was 1183 mg/kg of tobramycin or tobramycin equivalent. Twenty percent of courses resulted in AKI; 86% were Stage 1. A repeated measure multivariate model showed colistin, piperacillin/tazobactam, vancomycin, and age were significant AKI risk factors. There was no correlation between cumulative aminoglycoside dose and change in eGFR. AKI from IV aminoglycoside exposure occurred in 20% of courses. Cumulative exposure to IV aminoglycosides in APE management was not correlated with long‐term renal dysfunction.